Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 17/20 | 0.73 |
| ▸ | KEAP1 | Q14145 | 16/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494329 | 0.85 | NFE2L2 (1.00) | NFE2L2KEAP1SLC9A1SLC9A2HSD11B1 | |
| SCHEMBL6311969 | 0.84 | NFE2L2 (0.62) | NFE2L2KEAP1SLC9A1SLC9A2HSD11B1 | |
| SCHEMBL6313475 | 0.83 | TP53 (0.56) | NFE2L2KEAP1LMNARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6315561 | 0.83 | SLC9A1 (0.73) | NFE2L2KEAP1LMNARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6315553 | 0.82 | SMN1; SMN2 (0.52) | NFE2L2KEAP1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL3491956 | 0.79 | KEAP1 (0.86) | NFE2L2KEAP1SLC9A1SLC9A2HSD11B1 | |
| SCHEMBL1403045 | 0.79 | NFE2L2 (0.76) | NFE2L2KEAP1SLC9A1SLC9A2HSD11B1 | |
| SCHEMBL8341095 | 0.79 | KEAP1 (0.76) | NFE2L2KEAP1LMNASMN1; SMN2SLC9A1 | |
| SCHEMBL6312663 | 0.77 | SLC9A1 (0.71) | NFE2L2KEAP1SLC9A1SLC9A2 | |
| SCHEMBL21816347 | 0.77 | NFE2L2 (0.68) | NFE2L2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | NFE2L2 450/4885KEAP1 313/4885LMNA 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.